Skip to main content
Top
Published in: Journal of Neuro-Oncology 2/2019

01-04-2019 | Glioblastoma | Clinical Study

Effect of health disparities on overall survival of patients with glioblastoma

Authors: Jacob J. Mandel, Michael Youssef, Jooyeon Nam, Akash J. Patel, Ali Jalali, Ethan B. Ludmir, Diane Liu, Jimin Wu, Georgina Armstrong, Jason Huse, Melissa Bondy, John F. de Groot

Published in: Journal of Neuro-Oncology | Issue 2/2019

Login to get access

Abstract

Background

Examine the potential effects of health disparities in survival of glioblastoma (GB) patients.

Methods

We conducted a retrospective chart review of newly diagnosed GB patients from 2000 to 2015 at a free standing dedicated cancer center (MD Anderson Cancer Center—MDACC) and a safety net county hospital (Ben Taub General Hospital—BT) located in Houston, Texas. We obtained demographics, insurance status, extent of resection, treatments, and other known prognostic variables (Karnofsky Score—KPS) to evaluate their role on overall GB survival (OS).

Results

We identified 1073 GB patients consisting of 177 from BT and 896 from MDACC. We found significant differences by ethnicity, insurance status, KPS at diagnosis, extent of resection, and percentage of patients receiving standard of care (SOC) between the two centers. OS was 1.64 years for MDACC patients and 1.24 years for BT patients (p < 0.0176). Only 81 (45.8%) BT patients received SOC compared to 577 (64%) of MDACC patients (p < 0.0001). However, there was no significant difference in OS for patients who received SOC, 1.84 years for MDACC patients and 1.99 years for BT patients (p < 0.4787). Of the 96 BT patients who did not receive SOC, 29 (30%) had KPS less than 70 at time of diagnosis and 77 (80%) lacked insurance.

Conclusions

GB patients treated at a safety net county hospital had similar OS compared to a free standing comprehensive cancer center when receiving SOC. County hospital patients had poorer KPS at diagnosis and were often lacking health insurance affecting their ability to receive SOC.
Literature
2.
go back to reference Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996CrossRef Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996CrossRef
3.
go back to reference Polite BN, Adams-Campbell LL, Brawley OW et al (2017) Charting the future of cancer health disparities research: a position statement from the American Association for Cancer Research, the American CANCER SOCIETY, the American Society of Clinical Oncology, and the National Cancer Institute. J Clin Oncol 35(26):3075–3082CrossRefPubMed Polite BN, Adams-Campbell LL, Brawley OW et al (2017) Charting the future of cancer health disparities research: a position statement from the American Association for Cancer Research, the American CANCER SOCIETY, the American Society of Clinical Oncology, and the National Cancer Institute. J Clin Oncol 35(26):3075–3082CrossRefPubMed
4.
go back to reference National Institutes of Health. Cancer health disparities. cancer.gov/about-nci/organization/crchd/cancer-health-disparities-fact-sheet#q1. National Institutes of Health. Cancer health disparities. cancer.gov/about-nci/organization/crchd/cancer-health-disparities-fact-sheet#q1.
5.
go back to reference Shavers VL, Brown ML (2002) Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst 94(5):334–357CrossRefPubMed Shavers VL, Brown ML (2002) Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst 94(5):334–357CrossRefPubMed
6.
go back to reference Saadi A, Himmelstein DU, Woolhandler S, Mejia NI (2017) Racial disparities in neurologic health care access and utilization in the United States. Neurology 88(24):2268–2275CrossRefPubMedPubMedCentral Saadi A, Himmelstein DU, Woolhandler S, Mejia NI (2017) Racial disparities in neurologic health care access and utilization in the United States. Neurology 88(24):2268–2275CrossRefPubMedPubMedCentral
7.
go back to reference Vickrey BG, Shapiro MF (2009) Disparities research in neurology: an urgent need. Nat Rev Neurol 5:184CrossRefPubMed Vickrey BG, Shapiro MF (2009) Disparities research in neurology: an urgent need. Nat Rev Neurol 5:184CrossRefPubMed
8.
go back to reference Begley CE, Basu R, Reynolds T et al (2009) Sociodemographic disparities in epilepsy care: results from the Houston/New York City health care use and outcomes study. Epilepsia 50(5):1040–1050CrossRefPubMed Begley CE, Basu R, Reynolds T et al (2009) Sociodemographic disparities in epilepsy care: results from the Houston/New York City health care use and outcomes study. Epilepsia 50(5):1040–1050CrossRefPubMed
9.
10.
go back to reference Cunningham JE, Butler WM (2004) Racial disparities in female breast cancer in South Carolina: clinical evidence for a biological basis. Breast Cancer Res Treat 88(2):161–176CrossRefPubMed Cunningham JE, Butler WM (2004) Racial disparities in female breast cancer in South Carolina: clinical evidence for a biological basis. Breast Cancer Res Treat 88(2):161–176CrossRefPubMed
11.
go back to reference De La Fuente M, Ivan ME, Kimball J et al (2017) Epid-06. Genomic and clinical characterization of glioblastoma in hispanics. Neuro-oncology 19(suppl_6):vi70–vi70CrossRef De La Fuente M, Ivan ME, Kimball J et al (2017) Epid-06. Genomic and clinical characterization of glioblastoma in hispanics. Neuro-oncology 19(suppl_6):vi70–vi70CrossRef
12.
go back to reference Wu M, Miska J, Zhang P et al (2017) Path-44. race influences patient survival in glioma and associates with genetic markers of retinoic acid metabolism. Neuro-oncology 19(suppl_6):vi180–vi181CrossRefPubMedCentral Wu M, Miska J, Zhang P et al (2017) Path-44. race influences patient survival in glioma and associates with genetic markers of retinoic acid metabolism. Neuro-oncology 19(suppl_6):vi180–vi181CrossRefPubMedCentral
14.
go back to reference Rong X, Yang W, Garzon-Muvdi T et al (2016) Influence of insurance status on survival of adults with glioblastoma multiforme: a population-based study. Cancer 122(20):3157–3165CrossRefPubMed Rong X, Yang W, Garzon-Muvdi T et al (2016) Influence of insurance status on survival of adults with glioblastoma multiforme: a population-based study. Cancer 122(20):3157–3165CrossRefPubMed
15.
go back to reference Sommers BD, Gawande AA, Baicker K (2017) Health insurance coverage and health—what the recent evidence tells us. N Engl J Med 377(6):586–593CrossRefPubMed Sommers BD, Gawande AA, Baicker K (2017) Health insurance coverage and health—what the recent evidence tells us. N Engl J Med 377(6):586–593CrossRefPubMed
16.
go back to reference Harari A, Li N, Yeh MW (2014) Racial and socioeconomic disparities in presentation and outcomes of well-differentiated thyroid cancer. J Clin Endocrinol Metab 99(1):133–141CrossRefPubMed Harari A, Li N, Yeh MW (2014) Racial and socioeconomic disparities in presentation and outcomes of well-differentiated thyroid cancer. J Clin Endocrinol Metab 99(1):133–141CrossRefPubMed
17.
go back to reference Mahal AR, Mahal BA, Nguyen PL, Yu JB. Prostate cancer outcomes for men aged younger than 65 years with medicaid versus private insurance. Cancer 124(4):752–759 Mahal AR, Mahal BA, Nguyen PL, Yu JB. Prostate cancer outcomes for men aged younger than 65 years with medicaid versus private insurance. Cancer 124(4):752–759
18.
go back to reference Lawrence YR, Mishra MV, Werner-Wasik M et al (2012) Improving prognosis of glioblastoma in the 21st century: who has benefited most? Cancer 118(17):4228–4234CrossRefPubMed Lawrence YR, Mishra MV, Werner-Wasik M et al (2012) Improving prognosis of glioblastoma in the 21st century: who has benefited most? Cancer 118(17):4228–4234CrossRefPubMed
19.
go back to reference Aizer AA, Ancukiewicz M, Nguyen PL, Shih HA, Loeffler JS, Oh KS (2014) Underutilization of radiation therapy in patients with glioblastoma: predictive factors and outcomes. Cancer 120(2):238–243CrossRefPubMed Aizer AA, Ancukiewicz M, Nguyen PL, Shih HA, Loeffler JS, Oh KS (2014) Underutilization of radiation therapy in patients with glioblastoma: predictive factors and outcomes. Cancer 120(2):238–243CrossRefPubMed
20.
go back to reference Rhome R, Fisher R, Hormigo A, Parikh RR (2016) Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma. J Neuro-oncol 128(2):241–250CrossRef Rhome R, Fisher R, Hormigo A, Parikh RR (2016) Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma. J Neuro-oncol 128(2):241–250CrossRef
21.
go back to reference Brown DA, Himes BT, Kerezoudis P et al (2018) Insurance correlates with improved access to care and outcome among glioblastoma patients. Neuro-oncology Brown DA, Himes BT, Kerezoudis P et al (2018) Insurance correlates with improved access to care and outcome among glioblastoma patients. Neuro-oncology
22.
go back to reference Ellis L, Canchola AJ, Spiegel D, Ladabaum U, Haile R, Gomez SL. (2017) Trends in cancer survival by health insurance status in California from 1997 to 2014. JAMA Oncol 4(3):317–323 Ellis L, Canchola AJ, Spiegel D, Ladabaum U, Haile R, Gomez SL. (2017) Trends in cancer survival by health insurance status in California from 1997 to 2014. JAMA Oncol 4(3):317–323
23.
go back to reference Soni A, Sabik LM, Simon K, Sommers BD. (2017) Changes in insurance coverage among cancer patients under the affordable care act. JAMA Oncol 4(1):122–124 Soni A, Sabik LM, Simon K, Sommers BD. (2017) Changes in insurance coverage among cancer patients under the affordable care act. JAMA Oncol 4(1):122–124
24.
go back to reference Chino F, Suneja G, Moss H, Zafar SY, Havrilesky L, Chino JP. (2018) Healthcare disparities in cancer patients receiving radiation: changes in insurance status after medicaid expansion under the affordable care act. Int J Radiat Oncol Biol Phys 99(5):1320–1321CrossRef Chino F, Suneja G, Moss H, Zafar SY, Havrilesky L, Chino JP. (2018) Healthcare disparities in cancer patients receiving radiation: changes in insurance status after medicaid expansion under the affordable care act. Int J Radiat Oncol Biol Phys 99(5):1320–1321CrossRef
25.
go back to reference Brandes AA, Franceschi E, Ermani M et al (2014) Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: results from a prospective population-based registry. Could survival differ in a high-volume center? Neuro-oncol Pract 1(4):166–171CrossRef Brandes AA, Franceschi E, Ermani M et al (2014) Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: results from a prospective population-based registry. Could survival differ in a high-volume center? Neuro-oncol Pract 1(4):166–171CrossRef
26.
go back to reference Koshy M, Sher DJ, Spiotto M et al (2017) Association between hospital volume and receipt of treatment and survival in patients with glioblastoma. J Neuro-oncol 135(3):529–534CrossRef Koshy M, Sher DJ, Spiotto M et al (2017) Association between hospital volume and receipt of treatment and survival in patients with glioblastoma. J Neuro-oncol 135(3):529–534CrossRef
27.
go back to reference Zhu P, Du X, Zhu J-J, Esquenazi Y (2017) Hout-12. Improved survival of glioblastoma patients treated at academic cancer programs: a hospital-based study from the National Cancer Database. Neuro-oncology 19(suppl_6):vi108–vi108CrossRefPubMedCentral Zhu P, Du X, Zhu J-J, Esquenazi Y (2017) Hout-12. Improved survival of glioblastoma patients treated at academic cancer programs: a hospital-based study from the National Cancer Database. Neuro-oncology 19(suppl_6):vi108–vi108CrossRefPubMedCentral
28.
go back to reference Lynch JC, Welling L, Escosteguy C, Pereira AG, Andrade R, Pereira C (2013) Socioeconomic and educational factors interference in the prognosis for glioblastoma multiform. Br J Neurosurg 27(1):80–83CrossRefPubMed Lynch JC, Welling L, Escosteguy C, Pereira AG, Andrade R, Pereira C (2013) Socioeconomic and educational factors interference in the prognosis for glioblastoma multiform. Br J Neurosurg 27(1):80–83CrossRefPubMed
29.
go back to reference Loureiro LV, Pontes Lde B, Callegaro-Filho D et al (2014) Initial care and outcome of glioblastoma multiforme patients in 2 diverse health care scenarios in Brazil: does public versus private health care matter? Neuro-oncology 16(7):999–1005CrossRefPubMedPubMedCentral Loureiro LV, Pontes Lde B, Callegaro-Filho D et al (2014) Initial care and outcome of glioblastoma multiforme patients in 2 diverse health care scenarios in Brazil: does public versus private health care matter? Neuro-oncology 16(7):999–1005CrossRefPubMedPubMedCentral
30.
go back to reference Brandel MG, Rennert RC, Lopez Ramos C et al (2018) Management of glioblastoma at safety-net hospitals. J Neuro-oncol 139(2):389–397CrossRef Brandel MG, Rennert RC, Lopez Ramos C et al (2018) Management of glioblastoma at safety-net hospitals. J Neuro-oncol 139(2):389–397CrossRef
31.
go back to reference Ruiz-Sanchez D, Peinado II, Alaguero-Calero M, Sastre-Heres AJ, Diez BG, Pena-Diaz J (2016) Cost-effectiveness analysis of the bevacizumab-irinotecan regimen in the treatment of primary glioblastoma multiforme recurrences. Oncol Lett 12(3):1935–1940CrossRefPubMedPubMedCentral Ruiz-Sanchez D, Peinado II, Alaguero-Calero M, Sastre-Heres AJ, Diez BG, Pena-Diaz J (2016) Cost-effectiveness analysis of the bevacizumab-irinotecan regimen in the treatment of primary glioblastoma multiforme recurrences. Oncol Lett 12(3):1935–1940CrossRefPubMedPubMedCentral
32.
go back to reference Bernard-Arnoux F, Lamure M, Ducray F, Aulagner G, Honnorat J, Armoiry X (2016) The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro-oncology 18(8):1129–1136CrossRefPubMedPubMedCentral Bernard-Arnoux F, Lamure M, Ducray F, Aulagner G, Honnorat J, Armoiry X (2016) The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro-oncology 18(8):1129–1136CrossRefPubMedPubMedCentral
33.
go back to reference Kovic B, Xie F (2015) Economic evaluation of bevacizumab for the first-line treatment of newly diagnosed glioblastoma multiforme. J Clin Oncol 33(20):2296–2302CrossRefPubMed Kovic B, Xie F (2015) Economic evaluation of bevacizumab for the first-line treatment of newly diagnosed glioblastoma multiforme. J Clin Oncol 33(20):2296–2302CrossRefPubMed
34.
go back to reference Dropcho EJ (2012) Should the cost of care for patients with glioblastoma influence treatment decisions? Continuum 18(2):416–420PubMed Dropcho EJ (2012) Should the cost of care for patients with glioblastoma influence treatment decisions? Continuum 18(2):416–420PubMed
35.
go back to reference Mandel JJ, Yust-Katz S, Patel AJ et al (2017) Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro-oncology 20(1):113–122 Mandel JJ, Yust-Katz S, Patel AJ et al (2017) Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro-oncology 20(1):113–122
36.
go back to reference Chang SM, Barker FG 2nd, Schmidt MH et al (2002) Clinical trial participation among patients enrolled in the glioma outcomes project. Cancer 94(10):2681–2687CrossRefPubMed Chang SM, Barker FG 2nd, Schmidt MH et al (2002) Clinical trial participation among patients enrolled in the glioma outcomes project. Cancer 94(10):2681–2687CrossRefPubMed
37.
go back to reference Brooks SE, Muller CY, Robinson W et al (2015) Increasing minority enrollment onto clinical trials: practical strategies and challenges emerge from the NRG oncology accrual workshop. J Oncol Pract 11(6):486–490CrossRefPubMedPubMedCentral Brooks SE, Muller CY, Robinson W et al (2015) Increasing minority enrollment onto clinical trials: practical strategies and challenges emerge from the NRG oncology accrual workshop. J Oncol Pract 11(6):486–490CrossRefPubMedPubMedCentral
38.
go back to reference Ramirez AG, Thompson IM (2017) How will the ‘cancer moonshot’ impact health disparities? Cancer Causes Control 28(9):907–912CrossRefPubMed Ramirez AG, Thompson IM (2017) How will the ‘cancer moonshot’ impact health disparities? Cancer Causes Control 28(9):907–912CrossRefPubMed
39.
go back to reference Unger JM, Gralow JR, Albain KS, Ramsey SD, Hershman DL (2016) Patient income level and cancer clinical trial participation: a prospective survey study. JAMA Oncol 2(1):137–139CrossRefPubMedPubMedCentral Unger JM, Gralow JR, Albain KS, Ramsey SD, Hershman DL (2016) Patient income level and cancer clinical trial participation: a prospective survey study. JAMA Oncol 2(1):137–139CrossRefPubMedPubMedCentral
41.
go back to reference Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the Central Nervous System: a summary. Acta Neuropathol 131(6):803–820CrossRefPubMed Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the Central Nervous System: a summary. Acta Neuropathol 131(6):803–820CrossRefPubMed
Metadata
Title
Effect of health disparities on overall survival of patients with glioblastoma
Authors
Jacob J. Mandel
Michael Youssef
Jooyeon Nam
Akash J. Patel
Ali Jalali
Ethan B. Ludmir
Diane Liu
Jimin Wu
Georgina Armstrong
Jason Huse
Melissa Bondy
John F. de Groot
Publication date
01-04-2019
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 2/2019
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-019-03108-z

Other articles of this Issue 2/2019

Journal of Neuro-Oncology 2/2019 Go to the issue